While disease-modifying therapies largely steal the spotlight in Alzheimer’s drug development, several companies are working to solve this less-discussed but disruptive facet of the illness.

Bristol Myers Squibb

BMS said its experimental drug to treat Crohn’s disease, a chronic inflammatory bowel condition, did not help patients achieve disease remission in a late-stage study.


Moderna has entered into a development and commercialization funding agreement with asset management firm Blackstone Life Sciences to help advance its pipeline of flu vaccine candidates.

Avenzo Therapeutics on Tuesday said it will use the financing round to advance its next-generation oncology pipeline, including a potentially best-in-class CDK2 selective inhibitor.

Novocure said on Wednesday that its device met the main goal of a late-stage trial by slowing the progression of cancer to the brain in patients with a type of lung cancer, sending its shares up about 33% in before-the-bell trading.

Roche logo

Despite meeting its primary endpoint in a late-stage generalized myasthenia gravis trial, Roche and Chugai Pharmaceutical’s Enspryng did not demonstrate clinical benefit as expected, the companies announced Thursday.

Stemirna Therapeutics has halted an early stage trial for a new cancer vaccine, two of its trial researchers said, in a fresh setback to the company, which has been grappling with tight funding.

BMS, Bristol Myers Squibb

Bristol Myers Squibb secured another late-phase immuno-oncology victory Wednesday, showing that the combination of Opdivo and Yervoy improved overall survival in a patient population served by rival checkpoint inhibitors from AstraZeneca and Roche.

Bill & Melinda Gates Medical Research Institute

If shown to be well-tolerated and effective, M72/AS01E could potentially become the first vaccine to help prevent pulmonary TB in adolescents and adults, the most common form of the disease, and the first new TB vaccine in over a century. The first doses were given in South Africa, where TB takes a heavy toll.

Bluebird CFO Chris Krawtschuk in a statement said that the debt financing agreement with Hercules “underscores the value bluebird offers as a standalone gene therapy leader,” while also extending the biotech’s runway and “bolstering our ability to bring transformative treatments to patients and their families.”